Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14027202 | 0.90 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNANPSR1PKMMEN1 | |
| SCHEMBL14027543 | 0.77 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAMEN1KMT2ARECQL | |
| SCHEMBL14027274 | 0.75 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNANPSR1PKMMEN1 | |
| SCHEMBL14027549 | 0.72 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNAMEN1KMT2ARECQL | |
| SCHEMBL14027548 | 0.71 | RECQL (0.72) | SMN1; SMN2LMNANPSR1MEN1KMT2A | |
| SCHEMBL6207563 | 0.70 | RECQL (0.71) | SMN1; SMN2LMNARECQLTP53 | |
| SCHEMBL14027208 | 0.69 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4ECYP1A2CYP3A4 | |
| SCHEMBL23510063 | 0.69 | MEN1 (0.53) | SMN1; SMN2LMNANPSR1PKMMEN1 | |
| SCHEMBL5307236 | 0.69 | LMNA (0.55) | SMN1; SMN2LMNANPSR1PKMMEN1 | |
| SCHEMBL5351815 | 0.69 | ALDH1A1 (0.65) | SMN1; SMN2LMNANPSR1PKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446120-B2 | Peptidomimetic modulators of cell adhesion | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-11-04 | — | — | US | disclosed |
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-04-03 | — | — | US | disclosed |
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| US-7268115-B2 | Cyclic peptides; three-dimensional structures; screening; anticancer agents; angiogenesis inhibitors; drug delivery | ADHEREX TECHNOLOGIES, INC. (CA) | 2007-09-11 | — | — | US | disclosed |
| EP-1621539-A1 | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | CDH1, EPCAM, VCAM1 | SMN1; SMN2 4365/4885LMNA 1913/4885NPSR1 2182/4885 |
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | CDK1, PRKAR2B, MAP3K19 | SMN1; SMN2 4661/4885LMNA 2146/4885NPSR1 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.